Toxoplasma gondii-induced neuronal alterations

Parasite Immunology

Volumn 37, Issue 3, 2015, Pages 159-170

  Parlog, A ^a   Schluter D ^a,b   Dunay, I R ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Toxoplasma gondii; Behavioural manipulation; Chronic CNS infection; Neuronal alteration

Indexed keywords

DOPAMINE; GAMMA INTERFERON; GLUTAMATE RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; KYNURENIC ACID; NITRIC OXIDE; QUINOLINIC ACID; QUINOLINIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR; PARASITE ANTIGEN; PROTOZOAL PROTEIN;

APOPTOSIS; BASOLATERAL AMYGDALA; BEHAVIOR; BEHAVIOR CHANGE; CELL FUNCTION; CELL STRUCTURE; CENTRAL NERVOUS SYSTEM; CYST; DIFFUSION TENSOR IMAGING; DOPAMINE METABOLISM; HOST CELL; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNE SYSTEM; IN VITRO STUDY; MAJOR DEPRESSION; NERVE CELL; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PARASITE CLEARANCE; PERSONALITY; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; REVIEW; SCHIZOPHRENIA; TOXOPLASMA GONDII; TOXOPLASMOSIS; ANIMAL; BRAIN; COMPLICATION; DISEASE MODEL; IMMUNOLOGY; MENTAL DISEASE; METABOLISM; MOUSE; PARASITOLOGY; PATHOLOGY; PHYSIOLOGY; TOXOPLASMA;

MURINAE; TOXOPLASMA; TOXOPLASMA GONDII;

ANIMALS; ANTIGENS, PROTOZOAN; APOPTOSIS; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; MENTAL DISORDERS; MICE; NEURONS; PROTOZOAN PROTEINS; TOXOPLASMA; TOXOPLASMOSIS, CEREBRAL;

EID: 84923060232     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/pim.12157     Document Type: Review

References (182)

1. Hill DE, Chirukandoth S & Dubey JP. Biology and epidemiology of Toxoplasma gondii in man and animals. Anim Health Res Rev 2005; 6: 41-61.
2. Boothroyd JC & Grigg ME. Population biology of Toxoplasma gondii and its relevance to human infection: do different strains cause different disease? Curr Opin Microbiol 2002; 5: 438-442.
3. Montoya JG & Liesenfeld O. Toxoplasmosis. Lancet 2004; 363: 1965-1976.
4. Tenter AM, Heckeroth AR & Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol 2000; 30: 1217-1258.
5. Courret N, Darche S, Sonigo P, et al. CD11c- and CD11b-expressing mouse leukocytes transport single Toxoplasma gondii tachyzoites to the brain. Blood 2006; 107: 309-316.
6. Randall LM & Hunter CA. Parasite dissemination and the pathogenesis of toxoplasmosis. Eur J Microbiol Immunol (Bp) 2011; 1: 3-9.
7. Unno A, Suzuki K, Xuan X, et al. Dissemination of extracellular and intracellular Toxoplasma gondii tachyzoites in the blood flow. Parasitol Int 2008; 57: 515-518.
8. Fuks JM, Arrighi RBG, Weidner JM, et al. GABAergic signaling is linked to a hypermigratory phenotype in dendritic cells infected by Toxoplasma gondii. PLoS Pathog 2012; 8: e1003051.
9. Munoz M, Liesenfeld O & Heimesaat MM. Immunology of Toxoplasma gondii. Immunol Rev 2011; 240: 269-285.
10. Hunter CA, Roberts CW, Murray M & Alexander J. Detection of cytokine mRNA in the brains of mice with toxoplasmic encephalitis. Parasite Immunol 1992; 14: 405-413.
11. Hunter CA, Roberts CW & Alexander J. Kinetics of cytokine mRNA production in the brains of mice with progressive toxoplasmic encephalitis. Eur J Immunol 1992; 22: 2317-2322.
12. Wilson EH & Hunter CA. The role of astrocytes in the immunopathogenesis of toxoplasmic encephalitis. Int J Parasitol 2004; 34: 543-548.
13. Sarciron ME & Gherardi A. Cytokines involved in Toxoplasmic encephalitis. Scand J Immunol 2000; 52: 534-543.
14. Suzuki Y. Host resistance in the brain against Toxoplasma gondii. J Infect Dis 2002; 185: 58-65.
15. Suzuki Y. Immunopathogenesis of cerebral toxoplasmosis. J Infect Dis 2002; 186: 234-240.
16. Hunter CA & Sibley LD. Modulation of innate immunity by Toxoplasma gondii virulence effectors. Nat Rev Microbiol 2012; 10: 766-778.
17. Halonen SK, Lyman WD & Chiu FC. Growth and development of Toxoplasma gondii in human neurons and astrocytes. J Neuropathol Exp Neurol 1996; 55: 1150-1156.
18. Martens S, Parvanova I, Zerrahn J, et al. Disruption of Toxoplasma gondii parasitophorous vacuoles by the mouse p47-resistance GTPases. PLoS Pathog 2005; 1: 0187-0201.
19. Chao CC, Hu S, Gekker G, et al. Effects of cytokines on multiplication of Toxoplasma gondii in microglial cells. J Immunol 1993; 150: 3404-3410.
20. Creuzet C, Robert F, Roisin MP, et al. Neurons in primary culture are less efficiently infected by Toxoplasma gondii than glial cells. Parasitol Res 1998; 84: 25-30.
21. Fagard R, Van Tan H, Creuzet C & Pelloux H. Differential development of Toxoplasma gondii in neural cells. Parasitol Today 1999; 15: 504-507.
22. Ferguson DJ, Hutchison WM & Pettersen E. Tissue cyst rupture in mice chronically infected with Toxoplasma gondii. An immunocytochemical and ultrastructural study. Parasitol Res 1989; 75: 599-603.
23. Lüder CG, Giraldo-Velásquez M, Sendtner M & Gross U. Toxoplasma gondii in primary rat CNS cells: differential contribution of neurons, astrocytes, and microglial cells for the intracerebral development and stage differentiation. Exp Parasitol 1999; 93: 23-32.
24. Sims TA, Hay J & Talbot IC. An electron microscope and immunohistochemical study of the intracellular location of Toxoplasma tissue cysts within the brains of mice with congenital toxoplasmosis. Br J Exp Pathol 1989; 70: 317-325.
25. Melzer TC, Cranston HJ, Weiss LM & Halonen SK. Host cell preference of Toxoplasma gondii cysts in murine brain: a confocal study. J Neuroparasitology 2010; 1: 1-6.
26. Lyons RE, McLeod R & Roberts CW. Toxoplasma gondii tachyzoite-bradyzoite interconversion. Trends Parasitol 2002; 18: 198-201.
27. Schlüter D, Deckert M, Hof H & Frei K. Toxoplasma gondii infection of neurons induces neuronal cytokine and chemokine production, but gamma interferon- and tumor necrosis factor-stimulated neurons fail to inhibit the invasion. Infect Immun 2001; 69: 7889-7893.
28. Jebbari H, Roberts CW, Ferguson DJP, Bluethmann H & Alexander J. A protective role for IL-6 during early infection with Toxoplasma gondii. Parasite Immunol 1998; 20: 231-239.
29. Strack A, Asensio VC, Campbell IL, Schlüter D & Deckert M. Chemokines are differentially expressed by astrocytes, microglia and inflammatory leukocytes in Toxoplasma encephalitis and critically regulated by interferon-gamma. Acta Neuropathol 2002; 103: 458-468.
30. Fischer HG, Nitzgen B, Reichmann G & Hadding U. Cytokine responses induced by Toxoplasma gondii in astrocytes and microglial cells. Eur J Immunol 1997; 27: 1539-1548.
31. Schlüter D, Kaefer N, Hof H, Wiestler OD & Deckert-Schlüter M. Expression pattern and cellular origin of cytokines in the normal and Toxoplasma gondii-infected murine brain. Am J Pathol 1997; 150: 1021-1035.
32. Handel U, Brunn A, Drögemüller K, et al. Neuronal gp130 expression is crucial to prevent neuronal loss, hyperinflammation, and lethal course of murine Toxoplasma encephalitis. Am J Pathol 2012; 181: 163-173.
33. Schaeffer M, Han S-J, Chtanova T, et al. Dynamic imaging of T cell-parasite interactions in the brains of mice chronically infected with Toxoplasma gondii. J Immunol 2009; 182: 6379-6393.
34. Hutchinson WM, Bradley M, Cheyne WM, Wells BW & Hay J. Behavioural abnormalities in Toxoplasma-infected mice. Ann Trop Med Parasitol 1980; 74: 337-345.
35. Vyas A, Kim S-K, Giacomini N, Boothroyd JC & Sapolsky RM. Behavioral changes induced by Toxoplasma infection of rodents are highly specific to aversion of cat odors. Proc Natl Acad Sci USA 2007; 104: 6442-6447.
36. Haroon F, Handel U, Angenstein F, et al. Toxoplasma gondii actively inhibits neuronal function in chronically infected mice. PLoS One 2012; 7: e35516.
37. Hermes G, Ajioka JW, Kelly KA, et al. Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. J Neuroinflammation 2008; 5: 48.
38. Hay J, Hutchison WM, Aitken PP & Graham DI. The effect of congenital and adult-acquired Toxoplasma infections on activity and responsiveness to novel stimulation in mice. Ann Trop Med Parasitol 1983; 77: 483-495.
39. Gulinello M, Acquarone M, Kim JH, et al. Acquired infection with Toxoplasma gondii in adult mice results in sensorimotor deficits but normal cognitive behavior despite widespread brain pathology. Microbes Infect 2010; 12: 528-537.
40. Hay J, Aitken PP & Graham DI. Toxoplasma infection and response to novelty in mice. Z Parasitenkd 1984; 70: 575-588.
41. Ingram WM, Goodrich LM, Robey EA & Eisen MB. Mice infected with low-virulence strains of Toxoplasma gondii lose their innate aversion to cat urine, even after extensive parasite clearance. PLoS One 2013; 8: e75246.
42. Gatkowska J, Wieczorek M, Dziadek B, Dzitko K & Dlugonska H. Behavioral changes in mice caused by Toxoplasma gondii invasion of brain. Parasitol Res 2012; 111: 53-58.
43. Havlícek J, Gasová ZG, Smith AP, Zvára K & Flegr J. Decrease of psychomotor performance in subjects with latent "asymptomatic" toxoplasmosis. Parasitology 2001; 122: 515-520.
44. Beste C, Getzmann S, Gajewski PD, Golka K & Falkenstein M. Latent Toxoplasma gondii infection leads to deficits in goal-directed behavior in healthy elderly. Neurobiol Aging 2014; 35: 1037-1044.
45. Flegr J. Effects of Toxoplasma on human behavior. Schizophr Bull 2007; 33: 757-760.
46. Flegr J, Klose J, Novotná M, Berenreitterová M & Havlícek J. Increased incidence of traffic accidents in Toxoplasma-infected military drivers and protective effect RhD molecule revealed by a large-scale prospective cohort study. BMC Infect Dis 2009; 9: 72.
47. Flegr J, Havlícek J, Kodym P, Malý M & Smahel Z. Increased risk of traffic accidents in subjects with latent toxoplasmosis: a retrospective case-control study. BMC Infect Dis 2002; 2: 11.
48. Kocazeybek B, Oner YA, Turksoy R, et al. Higher prevalence of toxoplasmosis in victims of traffic accidents suggest increased risk of traffic accident in Toxoplasma-infected inhabitants of Istanbul and its suburbs. Forensic Sci Int 2009; 187: 103-108.
49. Yereli K, Balcioglu IC & Özbilgin A. Is Toxoplasma gondii a potential risk for traffic accidents in Turkey? Forensic Sci Int 2006; 163: 34-37.
50. Stock AK, Heintschel von Heinegg E, Köhling HL & Beste C. Latent Toxoplasma gondii infection leads to improved action control. Brain Behav Immun 2014; 37: 103-108.
51. Yolken RH, Dickerson FB & Fuller Torrey E. Toxoplasma and schizophrenia. Parasite Immunol 2009; 31: 706-715.
52. Flegr J & Hrdý I. Influence of chronic toxoplasmosis on some human personality factors. Folia Parasitol (Praha) 1994; 41: 122-126.
53. Flegr J, Zitková S, Kodym P & Frynta D. Induction of changes in human behaviour by the parasitic protozoan Toxoplasma gondii. Parasitology 1996; 113: 49-54.
54. Lindova J, Novotna M, Havlicek J, et al. Gender differences in behavioural changes induced by latent toxoplasmosis. Int J Parasitol 2006; 36: 8.
55. Flegr J, Lenochova P, Hodny Z & Vondrova M. Fatal attraction phenomenon in humans - cat odour attractiveness increased for Toxoplasma-infected men while decreased for infected women. PLoS Negl Trop Dis 2011; 5: e1389.
56. Mortensen PB, Nørgaard-Pedersen B, Waltoft BL, et al. Early infections of Toxoplasma gondii and the later development of schizophrenia. Schizophr Bull 2007; 33: 741-744.
57. Hinze-Selch D, Däubener W, Eggert L, et al. A controlled prospective study of Toxoplasma gondii infection in individuals with schizophrenia: beyond seroprevalence. Schizophr Bull 2007; 33: 782-788.
58. Torrey EF, Bartko JJ, Lun ZR & Yolken RH. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr Bull 2007; 33: 729-736.
59. Fabiani S, Pinto B & Bruschi F. Toxoplasmosis and neuropsychiatric diseases: can serological studies establish a clear relationship? Neurol Sci 2013; 34: 417-425.
60. Brown AS. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 2006; 32: 200-202.
61. Zhu S. Psychosis may be associated with toxoplasmosis. Med Hypotheses 2009; 73: 799-801.
62. Pedersen MG, Mortensen PB, Norgaard-Pedersen B & Postolache TT. Toxoplasma gondii infection and self-directed violence in mothers. Arch Gen Psychiatry 2012; 69: 1123-1130.
63. Berenreiterová M, Flegr J, Kuběna AA & Němec P. The distribution of Toxoplasma gondii cysts in the brain of a mouse with latent toxoplasmosis: implications for the behavioral manipulation hypothesis. PLoS One 2011; 6: e28925.
64. McConkey GA, Martin HL, Bristow GC & Webster JP. Toxoplasma gondii infection and behaviour - location, location, location? J Exp Biol 2013; 216: 113-119.
65. Parlog A, Harsan LA, Zagrebelsky M, et al. Chronic murine toxoplasmosis is defined by subtle changes in the neuronal connectivity. Dis Model Mech 2014; 7: 459-69.
66. Möhle L, Parlog A, Pahnke J & Dunay IR. Spinal cord pathology in chronic experimental Toxoplasma gondii infection. Eur J Microbiol Immunol (Bp) 2014; 4: 65-75.
67. Evans AK, Strassmann PS, Lee IP & Sapolsky RM. Patterns of Toxoplasma gondii cyst distribution in the forebrain associate with individual variation in predator odor avoidance and anxiety-related behavior in male Long-Evans rats. Brain Behav Immun 2014; 37: 122-133.
68. Maeda T, Fujii T, Matsumura T, et al. AIDS-related cerebral toxoplasmosis with hyperintense foci on T1-weighted MR images: a case report. J Infect 2006; 53: e167-70.
69. Suzuki K, Masuya M, Matsumoto T, et al. High-intensity signals in the basal ganglia from gadolinium-enhanced T1-weighted MRI as an early change in Toxoplasma encephalitis in an AIDS patient. J Infect Chemother 2010; 16: 135-138.
70. Schroeder PC, Post MJD, Oschatz E, et al. Analysis of the utility of diffusion-weighted MRI and apparent diffusion coefficient values in distinguishing central nervous system toxoplasmosis from lymphoma. Neuroradiology 2006; 48: 715-720.
71. Gaskell EA, Smith JE, Pinney JW, Westhead DR & McConkey GA. A unique dual activity amino acid hydroxylase in Toxoplasma gondii. PLoS One 2009; 4: e4801.
72. Prandovszky E, Gaskell E, Martin H, et al. The neurotropic parasite Toxoplasma gondii increases dopamine metabolism. PLoS One 2011; 6: e23866.
73. Money KM & Stanwood GD. Developmental origins of brain disorders: roles for dopamine. Front Cell Neurosci 2013; 7: 260.
74. Brisch R, Saniotis A, Wolf R, et al. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry 2014; 5: 47.
75. Hamon M & Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry 2013; 45: 54-63.
76. Mittal SK & Eddy C. The role of dopamine and glutamate modulation in Huntington disease. Behav Neurol 2013; 26: 255-263.
77. Segura-Aguilar J, Paris I, Muñoz P, et al. Protective and toxic roles of dopamine in Parkinson's disease. J Neurochem 2014; 129: 898-915.
78. Gatkowska J, Wieczorek M, Dziadek B, Dzitko K & Dlugonska H. Sex-dependent neurotransmitter level changes in brains of Toxoplasma gondii infected mice. Exp Parasitol 2013; 133: 1-7.
79. Stibbs HH. Changes in brain concentrations of catecholamines and indoleamines in Toxoplasma gondii infected mice. Ann Trop Med Parasitol 1985; 79: 153-157.
80. Koshy AA, Dietrich HK, Christian DA, et al. Toxoplasma co-opts host cells it does not invade. PLoS Pathog 2012; 8: 18.
81. Dubremetz JF. Rhoptries are major players in Toxoplasma gondii invasion and host cell interaction. Cell Microbiol 2007; 9: 841-848.
82. Graumann K, Hippe D, Groß U & Lüder CGK. Mammalian apoptotic signalling pathways: multiple targets of protozoan parasites to activate or deactivate host cell death. Microbes Infect 2009; 11: 1079-1087.
83. Payne TM, Molestina RE & Sinai AP. Inhibition of caspase activation and a requirement for NF-kappaB function in the Toxoplasma gondii-mediated blockade of host apoptosis. J Cell Sci 2003; 116: 4345-4358.
84. Ni Nyoman AD & Lüder CGK. Apoptosis-like cell death pathways in the unicellular parasite Toxoplasma gondii following treatment with apoptosis inducers and chemotherapeutic agents: a proof-of-concept study. Apoptosis 2013; 18: 664-680.
85. Goebel S, Gross U & Lüder CG. Inhibition of host cell apoptosis by Toxoplasma gondii is accompanied by reduced activation of the caspase cascade and alterations of poly(ADP-ribose) polymerase expression. J Cell Sci 2001; 114: 3495-3505.
86. Kim L & Denkers EY. Toxoplasma gondii triggers Gi-dependent PI 3-kinase signaling required for inhibition of host cell apoptosis. J Cell Sci 2006; 119: 2119-2126.
87. Orlofsky A, Weiss LM, Kawachi N & Prystowsky MB. Deficiency in the anti-apoptotic protein A1-a results in a diminished acute inflammatory response. J Immunol 2002; 168: 1840-1846.
88. Vutova P, Wirth M, Hippe D, et al. Toxoplasma gondii inhibits Fas/CD95-triggered cell death by inducing aberrant processing and degradation of caspase 8. Cell Microbiol 2007; 9: 1556-1570.
89. Dupont CD, Christian DA & Hunter CA. Immune response and immunopathology during toxoplasmosis. Semin Immunopathol 2012; 34: 793-813.
90. Wang X & Suzuki Y. Microglia produce IFN-gamma independently from T cells during acute toxoplasmosis in the brain. J Interferon Cytokine Res 2007; 27: 599-605.
91. Coogan A & O'Connor JJ. Inhibition of NMDA receptor-mediated synaptic transmission in the rat dentate gyrus in vitro by IL-1 beta. NeuroReport 1997; 8: 2107-2110.
92. Curran B & O'Connor JJ. The pro-inflammatory cytokine interleukin-18 impairs long-term potentiation and NMDA receptor-mediated transmission in the rat hippocampus in vitro. Neuroscience 2001; 108: 83-90.
93. Di Filippo M, Sarchielli P, Picconi B & Calabresi P. Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. Trends Pharmacol Sci 2008; 29: 402-412.
94. Buzoni-Gatel D & Werts C. Toxoplasma gondii and subversion of the immune system. Trends Parasitol 2006; 22: 448-452.
95. Denkers EY. Toll-like receptor initiated host defense against Toxoplasma gondii. J Biomed Biotechnol 2010; 2010: 737125.
96. Yarovinsky F. Innate immunity to Toxoplasma gondii infection. Nat Rev Immunol 2014; 14: 109-121.
97. Ju C-H, Chockalingam A & Leifer CA. Early response of mucosal epithelial cells during Toxoplasma gondii infection. J Immunol 2009; 183: 7420-7427.
98. + T cell-dependent, interferon-gamma-mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with Toxoplasma gondii. J Exp Med 1996; 184: 597-607.
99. Schreiner M & Liesenfeld O. Small intestinal inflammation following oral infection with Toxoplasma gondii does not occur exclusively in C57BL/6 mice: review of 70 reports from the literature. Mem Inst Oswaldo Cruz 2009; 104: 221-233.
100. Silva NM, Manzan RM, Carneiro WP, et al. Toxoplasma gondii: the severity of toxoplasmic encephalitis in C57BL/6 mice is associated with increased ALCAM and VCAM-1 expression in the central nervous system and higher blood-brain barrier permeability. Exp Parasitol 2010; 126: 167-177.
101. Dunay IR & Sibley LD. Monocytes mediate mucosal immunity to Toxoplasma gondii. Curr Opin Immunol 2010; 22: 461-466.
102. + inflammatory monocytes are required for mucosal resistance to the pathogen Toxoplasma gondii. Immunity 2008; 29: 306-317.
103. Gaddi PJ & Yap GS. Cytokine regulation of immunopathology in toxoplasmosis. Immunol Cell Biol 2007; 85: 155-159.
104. Carter CJ. Schizophrenia: a pathogenetic autoimmune disease caused by viruses and pathogens and dependent on genes. J Pathog 2011; 2011: 128318.
105. Haroon E, Raison CL & Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012; 37: 137-162.
106. Zheng X, Zhang X, Kang A, et al. Thinking outside the brain for cognitive improvement: is peripheral immunomodulation on the way? Neuropharmacology Elsevier Ltd; 2014.
107. Saper CB, Romanovsky AA & Scammell TE. Neural circuitry engaged by prostaglandins during the sickness syndrome. Nat Neurosci 2012; 15: 1088-1095.
108. Klein SL. Parasite manipulation of the proximate mechanisms that mediate social behavior in vertebrates. Physiol Behav 2003; 79: 441-449.
109. Kaushik M, Lamberton PHL & Webster JP. The role of parasites and pathogens in influencing generalised anxiety and predation-related fear in the mammalian central nervous system. Horm Behav 2012; 62: 191-201.
110. Kavaliers M & Colwell DD. Decreased predator avoidance in parasitized mice: neuromodulatory correlates. Parasitology 1995; 111: 257-263.
111. Nokes C & Bundy DA. Does helminth infection affect mental processing and educational achievement? Parasitol Today 1994; 10: 14-18.
112. Baruch K & Schwartz M. CNS-specific T cells shape brain function via the choroid plexus. Brain Behav Immun 2013; 34: 11-16.
113. Schwartz M & Baruch K. The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J 2014; 33: 7-20.
114. Quan N, Stern EL, Whiteside MB & Herkenham M. Induction of pro-inflammatory cytokine mRNAs in the brain after peripheral injection of subseptic doses of lipopolysaccharide in the rat. J Neuroimmunol 1999; 93: 72-80.
115. Wong D, Dorovini-Zis K & Vincent SR. Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood-brain barrier. Exp Neurol 2004; 190: 446-455.
116. Carruthers VB & Suzuki Y. Effects of Toxoplasma gondii infection on the brain. Schizophr Bull 2007; 33: 745-751.
117. Hunter CA & Remington JS. Immunopathogenesis of toxoplasmic encephalitis. J Infect Dis 1994; 170: 1057-1067.
118. Lyman M, Lloyd DG, Ji X, Vizcaychipi MP & Ma D. Neuroinflammation: the role and consequences. Neurosci Res 2014; 79: 1-12.
119. Najjar S, Pearlman DM, Alper K, Najjar A & Devinsky O. Neuroinflammation and psychiatric illness. J Neuroinflammation 2013; 10: 1-24.
120. Brietzke E, Stabellini R, Grassi-Oliveira R & Lafer B. Cytokines in bipolar disorder: recent findings, deleterious effects but promise for future therapeutics. CNS Spectr 2011; 16: 157-168.
121. Mansur RB, Zugman A, Asevedo EDM, et al. Cytokines in schizophrenia: possible role of anti-inflammatory medications in clinical and preclinical stages. Psychiatry Clin Neurosci 2012; 66: 247-260.
122. Miller BJ, Buckley P, Seabolt W, Mellor A & Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011; 70: 663-671.
123. Fritz-French C & Tyor W. Interferon-α (IFNα) neurotoxicity. Cytokine Growth Factor Rev 2012; 23: 7-14.
124. Zanelli S, Naylor M & Kapur J. Nitric oxide alters GABAergic synaptic transmission in cultured hippocampal neurons. Brain Res 2009; 1297: 23-31.
125. Zindler E & Zipp F. Neuronal injury in chronic CNS inflammation. Best Pract Res Clin Anaesthesiol 2010; 24: 551-562.
126. Giovannoni G, Heales SJR, Land JM & Thompson EJ. The potential role of nitric oxide in multiple sclerosis. Mult Scler 1998; 4: 212-216.
127. Law A, Gauthier S & Quirion R. Say NO to Alzheimer ' s disease : the putative links between nitric oxide and dementia of the Alzheimer ' s type. Brain Res Rev 2001; 35: 73-96.
128. Jung B-K, Pyo K-H, Shin KY, et al. Toxoplasma gondii Infection in the brain inhibits neuronal degeneration and learning and memory impairments in a murine model of Alzheimer's disease. PLoS One 2012; 7: e33312.
129. Rozenfeld C, Martinez R, Seabra S, et al. Toxoplasma gondii prevents neuron degeneration by interferon-gamma-activated microglia in a mechanism involving inhibition of inducible nitric oxide synthase and transforming growth factor-beta1 production by infected microglia. Am J Pathol 2005; 167: 1021-1031.
130. Esposito Z, Belli L, Toniolo S, et al. Amyloid β, glutamate, excitotoxicity in Alzheimer's disease: are we on the right track? CNS Neurosci Ther 2013; 19: 549-555.
131. Javitt DC. Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci 2010; 47: 4-16.
132. Anisman H, Merali Z & Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol 2008; 85: 1-74.
133. Dunn AJ & Wang J. Cytokine effects on CNS biogenic amines. NeuroImmunoModulation 1995; 2: 319-328.
134. Miller AH, Maletic V & Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65: 732-741.
135. Catena-Dell'Osso M, Rotella F, Dell'Osso A, Fagiolini A & Marazziti D. Inflammation, serotonin and major depression. Curr Drug Targets 2013; 14: 571-577.
136. Saito K, Markey SP & Heyes MP. Chronic effects of gamma-interferon on quinolinic acid and indoleamine-2, 3-dioxygenase in brain of C57BL6 mice. Brain Res 1991; 546: 151-154.
137. Zhu C-B, Lindler KM, Owens AW, et al. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology 2010; 35: 2510-2520.
138. Zhu C-B, Carneiro AM, Dostmann WR, Hewlett WA & Blakely RD. p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process. J Biol Chem 2005; 280: 15649-15658.
139. Moron JA, Zakharova I, Ferrer JV, et al. Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci 2003; 23: 8480-8488.
140. Neurauter G, Schröcksnadel K, Scholl-Bürgi S, et al. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab 2008; 9: 622-627.
141. Kitagami T, Yamada K, Miura H, et al. Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier. Brain Res 2003; 978: 104-114.
142. Schwarcz R & Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 2002; 303: 1-10.
143. Notarangelo FM, Wilson EH, Horning KJ, et al. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia. Schizophr Res 2014; 152: 261-267.
144. Guidetti P & Schwarcz R. 3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease? Adv Exp Med Biol 2003; 527: 137-145.
145. Guillemin GJ, Meininger V & Brew BJ. Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. Neurodegener Dis 2006; 2: 166-176.
146. Schwarcz R, Rassoulpour A, Wu HQ, et al. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001; 50: 521-530.
147. Guillemin GJ, Smythe G, Takikawa O & Brew BJ. Expression of indoleamine 2, 3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2005; 49: 15-23.
148. Bartlett TE & Wang YT. The intersections of NMDAR-dependent synaptic plasticity and cell survival. Neuropharmacology 2013; 74: 59-68.
149. Paoletti P, Bellone C & Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 2013; 14: 383-400.
150. Zhou Q & Sheng M. NMDA receptors in nervous system diseases. Neuropharmacology 2013; 74: 69-75.
151. Clinton SM & Meador-Woodruff JH. Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder. Neuropsychopharmacology 2004; 29: 1353-1362.
152. Eastwood SL. The synaptic pathology of schizophrenia: is aberrant neurodevelopment and plasticity to blame? Int Rev Neurobiol 2003; 59: 47-72.
153. Meador-Woodruff JH, Clinton SM, Beneyto M & McCullumsmith RE. Molecular abnormalities of the glutamate synapse in the thalamus in schizophrenia. Ann N Y Acad Sci 2003; 1003: 75-93.
154. Valtorta F, Pennuto M, Bonanomi D & Benfenati F. Synaptophysin: leading actor or walk-on role in synaptic vesicle exocytosis? BioEssays 2004; 26: 445-453.
155. Cao J, Viholainen JI, Dart C, et al. The PSD95-nNOS interface: a target for inhibition of excitotoxic p38 stress-activated protein kinase activation and cell death. J Cell Biol 2005; 168: 117-126.
156. Chetkovich DM, Bunn RC, Kuo S-H, et al. Postsynaptic targeting of alternative postsynaptic density-95 isoforms by distinct mechanisms. J Neurosci 2002; 22: 6415-6425.
157. Monfils MH & Teskey GC. Induction of long-term depression is associated with decreased dendritic length and spine density in layers III and V of sensorimotor neocortex. Synapse 2004; 53: 114-121.
158. Montgomery JM & Madison DV. Discrete synaptic states define a major mechanism of synapse plasticity. Trends Neurosci 2004; 27: 744-750.
159. Rajan I & Cline HT. Glutamate receptor activity is required for normal development of tectal cell dendrites in vivo. J Neurosci 1998; 18: 7836-7846.
160. Blanpied TA & Ehlers MD. Microanatomy of dendritic spines: emerging principles of synaptic pathology in psychiatric and neurological disease. Biol Psychiatry 2004; 55: 1121-1127.
161. Nimchinsky EA, Sabatini BL & Svoboda K. Structure and function of dendritic spines. Annu Rev Physiol 2002; 64: 313-353.
162. Glantz LA & Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 2000; 57: 65-73.
163. Kulkarni VA & Firestein BL. The dendritic tree and brain disorders. Mol Cell Neurosci 2012; 50: 10-20.
164. Van Spronsen M & Hoogenraad CC. Synapse pathology in psychiatric and neurologic disease. Curr Neurol Neurosci Rep 2010; 10: 207-214.
165. Mitra R, Sapolsky RM & Vyas A. Toxoplasma gondii infection induces dendritic retraction in basolateral amygdala accompanied by reduced corticosterone secretion. Dis Model Mech 2012; 6: 516-20.
166. Hansen MB. The enteric nervous system I: organisation and classification. Pharmacol Toxicol 2003; 92: 105-113.
167. Hansen MB. The enteric nervous system II: gastrointestinal functions. Pharmacol Toxicol 2003; 92: 249-257.
168. Hansen MB. The enteric nervous system III: a target for pharmacological treatment. Pharmacol Toxicol 2003; 93: 1-13.
169. Hermes-Uliana C, Pereira-Severi LS, Luerdes RB, et al. Chronic infection with Toxoplasma gondii causes myenteric neuroplasticity of the jejunum in rats. Auton Neurosci Basic Clin 2011; 160: 3-8.
170. Odorizzi L, Moreira NM, Gonçalves GF, et al. Quantitative and morphometric changes of subpopulations of myenteric neurons in swines with toxoplasmosis. Auton Neurosci Basic Clin 2010; 155: 68-72.
171. Papazian-Cabanas RM, Araújo EJA & da Silva AV. Sant'Ana DMG. Myenteric neuronal plasticity induced by Toxoplasma gondii (genotype III) on the duodenum of rats. An Acad Bras Cienc 2012; 84: 737-746.
172. Silva LS, Sartori AL, Zaniolo LM, et al. Toxoplasma gondii: myenteric neurons of intraperitoneally inoculated rats show quantitative and morphometric alterations. Exp Parasitol 2011; 129: 5-10.
173. Zaniolo LM, Da Silva AV, Sant'Ana D de MG & Araújo EJ de A. Toxoplasma gondii infection causes morphological changes in caecal myenteric neurons. Exp Parasitol 2012; 130: 103-109.
174. Stephan KE, Friston KJ & Frith CD. Dysconnection in Schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr Bull 2009; 35: 509-527.
175. Stephan KE, Baldeweg T & Friston KJ. Synaptic plasticity and dysconnection in schizophrenia. Biol Psychiatry 2006; 59: 929-939.
176. Vasic N, Walter H, Sambataro F & Wolf RC. Aberrant functional connectivity of dorsolateral prefrontal and cingulate networks in patients with major depression during working memory processing. Psychol Med 2009; 39: 977-987.
177. Zalesky A, Fornito A, Seal ML, et al. Disrupted axonal fiber connectivity in schizophrenia. Biol Psychiatry 2011; 69: 80-89.
178. Friston KJ. The disconnection hypothesis. Schizophr Res 1998; 30: 115-125.
179. Hahn C, Lim HK & Lee CU. Neuroimaging findings in late-onset schizophrenia and bipolar disorder. J Geriatr Psychiatry Neurol 2014; 27: 56-62.
180. Menzies L, Williams GB, Chamberlain SR, et al. White matter abnormalities in patients with obsessive-compulsive disorder and their first-degree relatives. Am J Psychiatry 2008; 165: 1308-1315.
181. Najjar S & Pearlman DM. Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res 2014.
182. Horacek J, Flegr J, Tintera J, et al. Latent toxoplasmosis reduces gray matter density in schizophrenia but not in controls: voxel-based-morphometry (VBM) study. World J Biol Psychiatry 2012; 13: 501-509.